Clinical Research Directory

Inclusion Criteria: 1. Age 16-65 years 2. Relapsed or refractory B cell malignancy following at least 2 prior lines of therapy: B-ALL: relapsed or refractory B-ALL following standard therapy, requiring salvage, in whom alternative therapies are deemed inappropriate by their treating physician Or LBCL: relapsed/refractory DLBCL (incl. transformed FL but not Richter's transformation) or PMBCL following ≥2 prior lines of therapy which must include Rituximab, anthracycline and autologous CD19 CAR, (unless CD19 CAR cannot be manufactured) Or MCL: relapsed/ refractory disease following ≥2 lines of therapy which must include Rituximab, Bruton's tyrosine kinase inhibitor and autologous CD19CAR therapy (unless CD19 CAR cannot be manufactured) Or Indolent B-NHL (either Follicular Lymphoma, Marginal Zone Lymphoma or other low-grade lymphoma) which is relapsed / refractory following ≥2 prior lines of therapy which must include anti-CD20 therapy and chemotherapy with anthracycline or bendamustine. 3. CD19+ disease 4. Agreement to have a pregnancy test, use adequate contraception (if applicable) 5. Written informed consent Exclusion Criteria: 1. CD19 negative disease 2. Active CNS involvement of disease 3. Diagnosis of chronic lymphocytic leukaemia/ small lymphocytic lymphoma or Burkitt lymphoma 4. Active hepatitis B, C or HIV infection 5. Oxygen saturation ≤ 90% on air 6. Bilirubin \>2 x upper limit of normal 7. GFR \<30ml/min 8. Women who are pregnant or breast feeding 9. Stem Cell Transplant patients only: active significant acute GvHD (overall Grade ≥ II, Modified Glucksberg criteria) or moderate/severe chronic GvHD (NIH consensus criteria) requiring immunosuppressive therapy and/or systemic steroids 10. Karnofsky score \<60% 11. Known allergy to albumin or DMSO 12. Patients receiving corticosteroids at a dose of \>5 mg prednisolone per day (or equivalent) that cannot be discontinued 13. Life expectancy \<3 months 14. Cardiac dysrhythmias (excluding well-controlled AF or other supraventricular tachycardia) or significant cardiac disease and left ventricular ejection fraction \<40% 15. Patients who can reasonably access autologous CD19 CAR treatment as part of standard of care or a clinical trial\* * These patients will be initially considered for autologous treatment in preference to enrolling on KCAT19